Related Experiment Videos
Resistance to anti-VEGF agents
1Department of Medical Oncology, Cancer Research UK, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. Nton@picr.man.ac.uk
Current Pharmaceutical Design
|February 3, 2004
Summary
Anti-angiogenic agents show disappointing single-agent activity due to tumor heterogeneity and VEGF signaling redundancy. Understanding these factors is crucial for developing effective anti-cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- The development of anti-angiogenic agents for cancer treatment has surged, with over 80 agents in clinical trials.
- Significant expectations were placed on these agents as a potential panacea for anti-tumoural treatment.
Purpose of the Study:
- To review factors contributing to the discrepancy between experimental and clinical findings for anti-angiogenic agents.
- To specifically examine inhibitors of Vascular Endothelial Growth Factor (VEGF) and their efficacy.
Main Methods:
- Review of current literature on anti-angiogenic agents in clinical and preclinical development.
- Analysis of factors influencing the activity of VEGF inhibitors in cancer therapy.
Main Results:
- Single-agent activity of anti-angiogenic therapies has been largely disappointing to date.
- A recent trial showed a survival advantage when chemotherapy was combined with anti-VEGF antibodies in advanced colorectal cancer.
- Tumor heterogeneity and redundancy in the VEGF signaling system are identified as key factors limiting efficacy.
Conclusions:
- Understanding tumor heterogeneity and VEGF pathway redundancy is critical for advancing anti-angiogenic drug development.
- Future generations of anti-angiogenic drugs must account for these biological complexities to improve patient outcomes.